Can a bone Drug's pain relief last? registry tracks CRPS-1 patients after neridronate
NCT ID NCT07811362
First seen Sep 10, 2026 · Last updated Sep 11, 2026 · Updated 1 time
Summary
This observational registry follows people with complex regional pain syndrome type 1 (CRPS-1) who received neridronate infusions in a separate clinical trial. For 12 to 24 months, participants answer online surveys about their pain, sleep, medication use, procedures, and daily function. Researchers want to see whether any pain relief from neridronate holds up over time and what other care people need.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- neridronate, a bisphosphonate drug given as an intravenous infusion
- What this could lead to
- If the registry shows neridronate's benefits last, it could support longer-term use and help doctors plan care for CRPS-1. It may also reveal which other treatments people still need.
- What could go wrong
- This is an observational registry, not a controlled trial, so it cannot prove neridronate causes any long-term effect. Participants know they received neridronate, and people who volunteer for follow-up may not represent everyone with CRPS-1.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 270 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
Apr 2029
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The registry target population for provisional enrollment includes all participants in CRPS-RISE, the parent trial of the Registry. After the completion of the last participant's last visit in CRPS-RISE and the unblinding of the trial, the Enrolled Study Cohort will be participants confirmed to have completed a four-infusion course of neridronate. The Enrolled Study Cohort will also include participants in the Open Label Extension study.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Participants from CRPS-RISE 1. Completion of four infusions of IP (neridronate 100 mg over a \~ 10-day period \[or the renally modified dosing, as applicable\] or placebo) in CRPS-RISE . 2. Completed CRPS-RISE with a final trial visit at Week 6 (Visit 8) or later. Participants who meet both criteria will be provisionally enrolled pending post-trial unblinding and be included in the Provisionally Enrolled Study Cohort. After CRPS-RISE last patient last visit unblinding, only participants who meet the following neridronate exposure criterion #3 will continue in registry follow-up and be included in the Enrolled Study Cohort: 3. Completion of 4-infusions of neridronate 100 mg over approximately a 10-day period in CRPS-RISE. * Participants from the Open Label Extension (OLE) 1. Completion of 4 infusions of neridronate 100 mg over approximately a 10-day period (or the renally modified dosing, as applicable) in the OLE. 2. Completed OLE with a final trial visit at Week 6 (Visit 8) or later. Exclusion Criteria: There are no exclusion criteria.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Complex regional pain syndrome I (CRPS I) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.